A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
An investigation of the efficacy and safety of up to 70 weeks of treatment with Tildacerfont
in subjects with classic CAH who have elevated biomarkers at baseline on their current GC
regimen.